Imatinib mesylate for chronic myeloid leukemia: what do we really know?
Husereau D
Record ID 32003000412
English, French
Authors' objectives:
To summarise the available evidence on imatinib mesylate (Gleevec(TM)) for chronic myeloid leukemia.
Authors' recommendations:
- Imatinib mesylate (GleevecTM) is a tyrosine kinase inhibitor, one of a new class of anti-cancer drugs called signal transduction inhibitors.
-A systematic review of case-series reports shows imatinib, when indirectly compared to conventional therapy, improves overall 12-month survival, but not surrogate outcomes, in individuals with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in myeloid-blast crisis, and accelerated phase. Surrogate outcomes, but not overall survival, were improved in chronic phase disease.
- Preliminary data from one randomized controlled trial suggest imatinib has a greater impact on surrogate outcomes compared to the combination of interferon-alpha and cytarabine in patients undergoing treatment for chronic phase Ph+ CML, however, it is not yet known whether it prolongs or improves quality of life.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antineoplastic Agents
- Leukemia, Myeloid
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.